Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis.
Goveia
Michelle
M
Chan
Benjamin P
BP
Patel
Priti R
PR
D000328:Adult; D016022:Case-Control Studies; D004347:Drug Interactions; D004921:Erythropoietin / Q000009:adverse effects*; D005260:Female; D005355:Fibrosis; D005682:Gadolinium / Q000009:adverse effects; D006397:Hematinics / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D019275:Radiopharmaceuticals / Q000009:adverse effects; D011994:Recombinant Proteins; D012307:Risk Factors; D012867:Skin / Q000473:pathology*; D012871:Skin Diseases / Q000139:chemically induced* / Q000209:etiology / Q000473:pathology
D006397:Hematinics; D019275:Radiopharmaceuticals; D011994:Recombinant Proteins; D004921:Erythropoietin; D005682:Gadolinium